Vaxart Inc (VXRT) - Total Assets
Based on the latest financial reports, Vaxart Inc (VXRT) holds total assets worth $208.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See VXRT total equity for net asset value and shareholders' equity analysis.
Vaxart Inc - Total Assets Trend (1985–2024)
This chart illustrates how Vaxart Inc's total assets have evolved over time, based on quarterly financial data.
Vaxart Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Vaxart Inc's total assets of $208.99 Million consist of 41.0% current assets and 59.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.2% |
| Accounts Receivable | $11.97 Million | 7.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.56 Million | 2.1% |
| Goodwill | $4.51 Million | 2.7% |
Asset Composition Trend (1985–2024)
This chart illustrates how Vaxart Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VXRT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxart Inc's current assets represent 41.0% of total assets in 2024, a decrease from 71.0% in 1985.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2024, up from 15.0% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 8.0% in 1985.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
Vaxart Inc Competitors by Total Assets
Key competitors of Vaxart Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Vaxart Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.69 | 0.83 | 10.93 |
| Quick Ratio | 0.69 | 0.88 | 10.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-51.93 Million | $-13.91 Million | $116.77 Million |
Vaxart Inc - Advanced Valuation Insights
This section examines the relationship between Vaxart Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.08 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | 81.2% |
| Total Assets | $166.39 Million |
| Market Capitalization | $135.87 Million USD |
Valuation Analysis
Near Book Valuation: The market values Vaxart Inc's assets close to their book value (0.82x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Vaxart Inc's assets grew by 81.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vaxart Inc (1985–2024)
The table below shows the annual total assets of Vaxart Inc from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $166.39 Million | +81.19% |
| 2023-12-31 | $91.83 Million | -40.31% |
| 2022-12-31 | $153.85 Million | -30.44% |
| 2021-12-31 | $221.17 Million | +44.95% |
| 2020-12-31 | $152.58 Million | +312.03% |
| 2019-12-31 | $37.03 Million | +5.12% |
| 2018-12-31 | $35.23 Million | -12.15% |
| 2017-12-31 | $40.10 Million | -44.84% |
| 2016-12-31 | $72.70 Million | -8.44% |
| 2015-12-31 | $79.40 Million | -30.35% |
| 2014-12-31 | $114.00 Million | +32.87% |
| 2013-12-31 | $85.80 Million | +1.78% |
| 2012-12-31 | $84.30 Million | -13.95% |
| 2011-12-31 | $97.97 Million | -13.97% |
| 2010-12-31 | $113.87 Million | -13.29% |
| 2009-12-31 | $131.32 Million | -8.95% |
| 2008-12-31 | $144.22 Million | -39.55% |
| 2007-12-31 | $238.57 Million | -10.27% |
| 2006-12-31 | $265.88 Million | -19.27% |
| 2005-12-31 | $329.34 Million | -10.55% |
| 2004-12-31 | $368.17 Million | -4.94% |
| 2003-12-31 | $387.30 Million | +66.35% |
| 2002-12-31 | $232.82 Million | -24.97% |
| 2001-12-31 | $310.31 Million | +38.23% |
| 2000-12-31 | $224.49 Million | +4.61% |
| 1999-12-31 | $214.60 Million | -1.69% |
| 1998-12-31 | $218.30 Million | -3.36% |
| 1997-12-31 | $225.90 Million | +11.78% |
| 1996-12-31 | $202.10 Million | +46.45% |
| 1995-12-31 | $138.00 Million | +47.12% |
| 1994-12-31 | $93.80 Million | +77.32% |
| 1993-12-31 | $52.90 Million | +11.37% |
| 1992-12-31 | $47.50 Million | +78.57% |
| 1991-12-31 | $26.60 Million | +12.24% |
| 1990-12-31 | $23.70 Million | -2.87% |
| 1989-12-31 | $24.40 Million | +16.75% |
| 1988-12-31 | $20.90 Million | +53.68% |
| 1987-12-31 | $13.60 Million | +1.49% |
| 1986-12-31 | $13.40 Million | +34.00% |
| 1985-12-31 | $10.00 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus v… Read more